Adicet Bio Management
Management criteria checks 2/4
Adicet Bio's CEO is Chen Schor, appointed in Sep 2020, has a tenure of 3.75 years. total yearly compensation is $5.97M, comprised of 10.1% salary and 89.9% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $180.76K. The average tenure of the management team and the board of directors is 3.7 years and 3.3 years respectively.
Key information
Chen Schor
Chief executive officer
US$6.0m
Total compensation
| CEO salary percentage | 10.1% |
| CEO tenure | 3.8yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3.7yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Adicet Bio: Microcap With A High Risk To Reward Ratio
May 23Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate
Feb 01
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth?
Dec 07Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?
Aug 07Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans
Apr 20Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation
Dec 20Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio
Oct 17Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?
Oct 04Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term
Aug 16Adicet Bio: A First Take
Jul 22Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans
Jul 07Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit
May 15We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate
Mar 18Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate
Feb 09Adicet: Promising 2021 Therapeutic Initiations, Cash Of $108 Million, And New Management
Dec 28Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans
Dec 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$140m |
| Dec 31 2023 | n/a | n/a | -US$143m |
| Sep 30 2023 | n/a | n/a | -US$143m |
| Jun 30 2023 | n/a | n/a | -US$115m |
| Mar 31 2023 | n/a | n/a | -US$105m |
| Dec 31 2022 | US$4m | US$562k | -US$70m |
| Sep 30 2022 | n/a | n/a | -US$56m |
| Jun 30 2022 | n/a | n/a | -US$48m |
| Mar 31 2022 | n/a | n/a | -US$36m |
| Dec 31 2021 | US$10m | US$536k | -US$62m |
| Sep 30 2021 | n/a | n/a | -US$55m |
| Jun 30 2021 | n/a | n/a | -US$56m |
| Mar 31 2021 | n/a | n/a | -US$54m |
| Dec 31 2020 | US$11m | US$499k | -US$37m |
Compensation vs Market: Chen's total compensation ($USD5.97M) is above average for companies of similar size in the US market ($USD678.50K).
Compensation vs Earnings: Chen's compensation has increased whilst the company is unprofitable.
CEO
Chen Schor (52 yo)
3.8yrs
Tenure
US$5,973,807
Compensation
Mr. Chen Schor, MBA, BA, CPA, has been the Chief Executive Officer, President & Director at Adicet Bio, Inc since September 15, 2020. He was a Co-Founder of resTORbio, Inc. and served as its President and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 3.8yrs | US$5.97m | 0.16% $ 180.8k | |
| Founder & Independent Director | no data | US$240.29k | 1.04% $ 1.1m | |
| Chief Financial Officer | 3.8yrs | US$2.13m | 0.068% $ 75.2k | |
| Chief Technology Officer | 3.7yrs | US$2.09m | 0.043% $ 47.2k | |
| Senior VP & Chief Scientific Officer | 3.2yrs | US$2.48m | 0.031% $ 34.0k | |
| Chief Human Resource Officer | 2.4yrs | no data | no data | |
| Chief Medical Officer & Senior VP | 3.8yrs | US$1.99m | 0.092% $ 101.2k | |
| Senior VP & Chief Regulatory Officer | 1.6yrs | no data | no data |
3.7yrs
Average Tenure
59yo
Average Age
Experienced Management: ACET's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 3.8yrs | US$5.97m | 0.16% $ 180.8k | |
| Founder & Independent Director | 3.8yrs | US$240.29k | 1.04% $ 1.1m | |
| Independent Chairman | 3.8yrs | US$275.29k | 0.0072% $ 7.9k | |
| Independent Director | 3.8yrs | US$254.29k | 0.013% $ 14.6k | |
| Independent Director | 3.3yrs | US$255.29k | 0.0072% $ 7.9k | |
| Independent Director | 3.8yrs | US$240.29k | 0.0072% $ 7.9k | |
| Member of Scientific Advisory Board | 2.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.3yrs | US$2.90m | no data | |
| Member of Scientific Advisory Board | 2.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.9yrs | no data | no data |
3.3yrs
Average Tenure
67yo
Average Age
Experienced Board: ACET's board of directors are considered experienced (3.3 years average tenure).